GSK-TRX103635



A randomized, double-blind, multi-center, placebo-controlled, cross-over study to determine the consistency of response for Trexima* (sumatriptan 85mg/naproxen sodium 500mg) administered during the mild pain phase for the acute treatment of multiple migraine attacks (*Treximet)
sumatriptan/naproxen
TRX103635
NCT00240617
Migraine Disorders
Phase 3
 
July 2015